Literature DB >> 11246354

Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C.

C W Chu1, S J Hwang, J C Luo, C R Lai, S H Tsay, C P Li, J C Wu, F Y Chang, S D Lee.   

Abstract

Elevated serum alpha-fetoprotein (AFP) in patients with chronic hepatitis C is not uncommonly seen, but the pathogenesis of this phenomenon remains unclear. The aims of this study were to assess the prevalence of elevated serum AFP in patients with chronic hepatitis C and to evaluate the clinical, virologic, and histopathologic significance of this phenomenon. One hundred and fifteen Chinese patients with a histologic diagnosis of chronic hepatitis C were enrolled. None had evidence of hepatocellular carcinoma by image study at enrollment and for at least 2 years' follow-up. Of the 115 patients, 33 (29%) had elevated serum AFP (more than 12 ng/mL). There was a significantly lower mean serum albumin (4.0 +/- 0.1 vs. 4.3 +/- 0.1 gm/dL, p <0.001) and higher mean scores for periportal necroinflammation (3.3 +/- 0.3 vs. 2.3 +/- 0.2, p = 0.007) and fibrosis (2.3 +/- 0.2 vs. 1.1 +/- 0.1, p < 0.001) in patients with elevated serum AFP when compared with patients without elevated serum AFP. Patients with elevated serum AFP had significantly more incidences of genotype 1b infection when compared with patients without elevated serum AFP (77% vs. 51%, p = 0.021). Mean serum hepatitis C virus (HCV) RNA titer showed no significant difference between the two groups. Multivariate logistic regression analysis showed that as serum albumin of less than 4.2 gm/dL, a histology fibrotic score of more than 3, and HCV genotype 1b infection were significantly independent predictors associated with elevated serum AFP. In conclusion, elevated serum AFP levels were significantly correlated with lower serum albumin levels, advanced fibrosis/cirrhosis, and genotype 1b infection in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246354     DOI: 10.1097/00004836-200103000-00014

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  31 in total

1.  New Prognostic Markers: The Pathway from Research to Clinical Practice.

Authors:  Caroline Savage; Andrew J Vickers
Journal:  Grand rounds Urol       Date:  2009-08

2.  Cyclooxygenase-2 single-nucleotide polymorphisms and hepatocellular carcinoma in Egypt.

Authors:  Faten Zahran Mohamed; Yousry Mostafa Hussein; Ibrahim Mohey El-Deen; Marwa Sayed Sabea
Journal:  Mol Biol Rep       Date:  2014-01-08       Impact factor: 2.316

3.  Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus.

Authors:  Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Toshifumi Tada; Junko Tanaka; Hiroshi Yoshizawa
Journal:  J Gastroenterol       Date:  2010-12-07       Impact factor: 7.527

4.  Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.

Authors:  Yasushi Tamura; Masato Igarashi; Hirokazu Kawai; Takeshi Suda; Shinji Satomura; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2010-04-21       Impact factor: 3.199

5.  Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Authors:  Yasushi Tamura; Takeshi Suda; Shigeki Arii; Michio Sata; Fuminori Moriyasu; Hiroshi Imamura; Seiji Kawasaki; Namiki Izumi; Tadatoshi Takayama; Norihiro Kokudo; Masakazu Yamamoto; Hiroko Iijima; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

6.  Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Yasushi Tamura; Satoshi Yamagiwa; Yohei Aoki; So Kurita; Takeshi Suda; Shogo Ohkoshi; Minoru Nomoto; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

7.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

8.  Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis.

Authors:  Myron John Tong; Thatcher Thi Huynh; Surachate Siripongsakun; Patrick Weijen Chang; Lori Terese Tong; Yen Phi Ha; Edward Alphonso Mena; Matthew Frank Weissman
Journal:  Hepatol Int       Date:  2015-07-30       Impact factor: 6.047

9.  Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection.

Authors:  Samer S El-Kamary; Mona M Mohamed; Maissa El-Raziky; Michelle D Shardell; Olfat G Shaker; Wafaa A ElAkel; Gamal Esmat
Journal:  Liver Int       Date:  2013-03-20       Impact factor: 5.828

10.  Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma.

Authors:  Tung Huynh; Ke-Qin Hu
Journal:  Front Med       Date:  2019-10-26       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.